TY - JOUR
T1 - The diazoxide derivative 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4- benzothiadiazine-S,S-dioxide augments AMPA- and GABA-mediated synaptic responses in cultured hippocampal neurons
AU - Yamada, Kelvin A.
AU - Hill, Matthew W.
AU - Hu, Yuefei
AU - Covey, Douglas F.
N1 - Funding Information:
This work was supported by NIH Grants NS 32636 and AG 05681. We are grateful to Nancy Lancaster for preparing and maintaining hippocampal neuron cultures and for performing in vitro excitotoxic-ity experiments. Dr. Erminio Costa graciously provided IDRA21 for initial studies. Some of these data were presented at the annual meeting of the Child Neurology Society in Minneapolis, Minnesota, 1996.
PY - 1998/9
Y1 - 1998/9
N2 - The diazoxide derivative 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4- benzothiadiazine-S,S-dioxide (IDRA21) enhances memory and learning in rodents, most likely by potentiating AMPAergic synaptic activity. We examined IDRA21's effect upon AMPAergic synaptic currents and whole-cell glutamate currents in cultured rat hippocampal neurons to determine whether IDRA21 was a partial modulator of AMPA receptor desensitization and deactivation. Comparable to cyclothiazide, IDRA21 prolonged AMPAergic autaptic currents (5.6 times control, EC50 150 μM) and slowed the rate of AMPA deactivation (3 times control) following 1-ms applications of 1 mM glutamate to excised, outside-out membrane patches. IDRA21 also augmented autaptic GABA currents by 27 ± 8.1%, although it had two opposing effects, reducing the peak amplitude versus prolonging autaptic GABA currents. IDRA21 (200 μM) inhibited whole- cell GABA currents elicited by exogenously applied 1 mM GABA by 41 ± 11%. At sufficient concentrations, IDRA21 reduced AMPA receptor desensitization and slowed the rate of deactivation, most consistent with full agonist activity with lower potency compared to cyclothiazide. IDRA21 slightly augments GABAergic synaptic currents.
AB - The diazoxide derivative 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4- benzothiadiazine-S,S-dioxide (IDRA21) enhances memory and learning in rodents, most likely by potentiating AMPAergic synaptic activity. We examined IDRA21's effect upon AMPAergic synaptic currents and whole-cell glutamate currents in cultured rat hippocampal neurons to determine whether IDRA21 was a partial modulator of AMPA receptor desensitization and deactivation. Comparable to cyclothiazide, IDRA21 prolonged AMPAergic autaptic currents (5.6 times control, EC50 150 μM) and slowed the rate of AMPA deactivation (3 times control) following 1-ms applications of 1 mM glutamate to excised, outside-out membrane patches. IDRA21 also augmented autaptic GABA currents by 27 ± 8.1%, although it had two opposing effects, reducing the peak amplitude versus prolonging autaptic GABA currents. IDRA21 (200 μM) inhibited whole- cell GABA currents elicited by exogenously applied 1 mM GABA by 41 ± 11%. At sufficient concentrations, IDRA21 reduced AMPA receptor desensitization and slowed the rate of deactivation, most consistent with full agonist activity with lower potency compared to cyclothiazide. IDRA21 slightly augments GABAergic synaptic currents.
KW - AMPA
KW - Autapse
KW - Benzothiadiazine
KW - Cyclothiazide
KW - Excitatory postsynaptic current
KW - Thiazide
UR - http://www.scopus.com/inward/record.url?scp=0031797872&partnerID=8YFLogxK
U2 - 10.1006/nbdi.1998.0196
DO - 10.1006/nbdi.1998.0196
M3 - Article
C2 - 9848091
AN - SCOPUS:0031797872
SN - 0969-9961
VL - 5
SP - 196
EP - 205
JO - Neurobiology of Disease
JF - Neurobiology of Disease
IS - 3
ER -